Mo Chen
Impact in
- Cancer Research top 10%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Drug Discovery top 10%
Papers in
-
- Ovarian cancer diagnosis and treatment 7
- Endometriosis Research and Treatment 2
- Co-authors
- T.M. Penning (3 shared papers)Liangqing Yao (10 shared papers)Adegoke O. Adeniji (1 shared paper)Jie Wu (3 shared papers)Liangqing Yao (11 shared papers)Congjian Xu (3 shared papers)Danqing Zheng (1 shared paper)Yifeng He (3 shared papers)
- Journals
- International Journal of Gynecological Cancer (3 papers)Orthopaedic Journal of Sports Medicine (3 papers)Medicine (2 papers)Organic Chemistry Frontiers (2 papers)Journal of Translational Medicine (2 papers)
- Partner nations
- ChinaUnited StatesPortugal
In The Last Decade
Mo Chen
45 papers receiving 962 citations
Peers
Comparison fields: 5 of 97
- Cancer Research 177
- Drug Discovery 2
- Cell Biology 104
- Organic Chemistry 180
- Oncology 140
Countries citing papers authored by Mo Chen
This map shows the geographic impact of Mo Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mo Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mo Chen more than expected).
Fields of papers citing papers by Mo Chen
This network shows the impact of papers produced by Mo Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mo Chen. The network helps show where Mo Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Mo Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 120 | |
| 2 | 2016 | 98 | |
| 3 | 2021 | 93 | |
| 4 | 2016 | 77 | |
| 5 | 2013 | 58 | |
| 6 | 2017 | 54 | |
| 7 | 2019 | 50 | |
| 8 | 2010 | 47 | |
| 9 | 2018 | 42 | |
| 10 | 2011 | 28 | |
| 11 | CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer. | 2020 | 26 |
| 12 | 2020 | 25 | |
| 13 | 2021 | 24 | |
| 14 | 2018 | 22 | |
| 15 | 2022 | 21 | |
| 16 | 2016 | 21 | |
| 17 | 2012 | 18 | |
| 18 | 2022 | 14 | |
| 19 | 2021 | 14 | |
| 20 | 2016 | 10 |
About Mo Chen
Mo Chen is a scholar working on Molecular Biology, Reproductive Medicine, Surgery, Oncology and Obstetrics and Gynecology, having authored 51 papers that have together received 966 indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (7 papers), Endometrial and Cervical Cancer Treatments (4 papers), Colorectal Cancer Surgical Treatments (3 papers), Catalytic C–H Functionalization Methods (3 papers), Shoulder Injury and Treatment (3 papers), Uterine Myomas and Treatments (3 papers), Endometriosis Research and Treatment (2 papers) and Gynecological conditions and treatments (2 papers). The work is most often cited by research in Cancer Research (177 citations), Drug Discovery (2 citations), Cell Biology (104 citations), Organic Chemistry (180 citations) and Oncology (140 citations). Mo Chen has collaborated with scholars based in China, United States and Portugal. Frequent co-authors include T.M. Penning, Liangqing Yao, Adegoke O. Adeniji, Jie Wu, Liangqing Yao, Congjian Xu, Danqing Zheng, Yifeng He, Xiuling Zhi and Yuting Huang. Their work appears in journals such as International Journal of Gynecological Cancer, Orthopaedic Journal of Sports Medicine, Medicine, Organic Chemistry Frontiers and Journal of Translational Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.